PCN81 - BUDGET IMPACT ANALYSIS OF CDK4/6 INHIBITORS FOR THE FIRST LINE THERAPHY OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN THE RUSSIAN FEDERATION
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.163
https://www.valueinhealthjournal.com/article/S1098-3015(18)33463-6/fulltext
Title :
PCN81 - BUDGET IMPACT ANALYSIS OF CDK4/6 INHIBITORS FOR THE FIRST LINE THERAPHY OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN THE RUSSIAN FEDERATION
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33463-6&doi=10.1016/j.jval.2018.09.163
First page :
Section Title :
Open access? :
No
Section Order :
1037